NCT05493631View on ClinicalTrials.gov

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

PHASE1UnknownINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2024

Conditions

Hemophilia

Interventions

BIOLOGICAL

MG1113

MG1113 subcutaneous (SC) injection

Trial Locations (1)

16924

RECRUITING

GC Biopharma Corp., Yongin-si

Sponsors

Lead Sponsor

GC Biopharma Corp

All Listed Sponsors

lead

GC Biopharma Corp

INDUSTRY

NCT05493631 - A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient | Biotech Hunter | Biotech Hunter